Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Class A Common Stock
-
Shares outstanding
-
60.6M
-
Number of holders
-
52
-
Total 13F shares, excl. options
-
16.1M
-
Shares change
-
-857K
-
Total reported value, excl. options
-
$119M
-
Value change
-
-$6.3M
-
Number of buys
-
19
-
Number of sells
-
-21
-
Price
-
$7.35
Significant Holders of Immuneering Corp - Class A Common Stock (IMRX) as of Q4 2023
55 filings reported holding IMRX - Immuneering Corp - Class A Common Stock as of Q4 2023.
Immuneering Corp - Class A Common Stock (IMRX) has 52 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.1M shares
of 60.6M outstanding shares and own 26.62% of the company stock.
Largest 10 shareholders include Cormorant Asset Management, LP (4.2M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.38M shares), BlackRock Inc. (2.1M shares), CITADEL ADVISORS LLC (2.08M shares), VANGUARD GROUP INC (1.07M shares), FMR LLC (489K shares), GOLDMAN SACHS GROUP INC (457K shares), GEODE CAPITAL MANAGEMENT, LLC (444K shares), STATE STREET CORP (374K shares), and HighVista Strategies LLC (255K shares).
This table shows the top 52 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.